{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["IBS", "STW 5", "UHPLC-HRMS", "metabolomics", "microbiome", "next-generation sequencing"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38738925", "DateCompleted": {"Year": "2024", "Month": "06", "Day": "05"}, "DateRevised": {"Year": "2024", "Month": "08", "Day": "07"}, "Article": {"Language": ["eng"], "ELocationID": ["e04031-23", "10.1128/spectrum.04031-23"], "ArticleDate": [{"Year": "2024", "Month": "05", "Day": "13"}], "Journal": {"ISSN": "2165-0497", "JournalIssue": {"Volume": "12", "Issue": "6", "PubDate": {"Year": "2024", "Month": "Jun", "Day": "04"}}, "Title": "Microbiology spectrum", "ISOAbbreviation": "Microbiol Spectr"}, "ArticleTitle": "Rapid biotransformation of STW 5 constituents by human gut microbiome from IBS- and non-IBS donors.", "Pagination": {"StartPage": "e0403123", "MedlinePgn": "e0403123"}, "Abstract": {"AbstractText": ["STW 5, a blend of nine medicinal plant extracts, exhibits promising efficacy in treating functional gastrointestinal disorders, notably irritable bowel syndrome (IBS). Nonetheless, its effects on the gastrointestinal microbiome and the role of microbiota on the conversion of its constituents are still largely unexplored. This study employed an experimental <i>ex vivo</i> model to investigate STW 5's differential effects on fecal microbial communities and metabolite production in samples from individuals with and without IBS. Using 560 fecal microcosms (IBS patients, <i>n</i> = 6; healthy controls, <i>n</i> = 10), we evaluated the influence of pre-digested STW 5 and controls on microbial and metabolite composition at time points 0, 0.5, 4, and 24 h. Our findings demonstrate the potential of this <i>ex vivo</i> platform to analyze herbal medicine turnover within 4 h with minimal microbiome shifts due to abiotic factors. While only minor taxonomic disparities were noted between IBS- and non-IBS samples and upon treatment with STW 5, rapid metabolic turnover of STW 5 components into specific degradation products, such as 18\u03b2-glycyrrhetinic acid, davidigenin, herniarin, 3-(3-hydroxyphenyl)propanoic acid, and 3-(2-hydroxy-4-methoxyphenyl)propanoic acid occurred. For davidigenin, 3-(3-hydroxyphenyl)propanoic acid and 18\u03b2-glycyrrhetinic acid, anti-inflammatory, cytoprotective, or spasmolytic activities have been previously described. Notably, the microbiome-driven metabolic transformation did not induce a global microbiome shift, and the detected metabolites were minimally linked to specific taxa. Observed biotransformations were independent of IBS diagnosis, suggesting potential benefits for IBS patients from biotransformation products of STW 5.", "STW 5 is an herbal medicinal product with proven clinical efficacy in the treatment of functional gastrointestinal disorders, like functional dyspepsia and irritable bowel syndrome (IBS). The effects of STW 5 on fecal microbial communities and metabolite production effects have been studied in an experimental model with fecal samples from individuals with and without IBS. While only minor taxonomic disparities were noted between IBS- and non-IBS samples and upon treatment with STW 5, rapid metabolic turnover of STW 5 components into specific degradation products with reported anti-inflammatory, cytoprotective, or spasmolytic activities was observed, which may be relevant for the pharmacological activity of STW 5."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria."}, {"Identifier": [], "Affiliation": "BioTechMed, Graz, Austria."}], "LastName": "Thumann", "ForeName": "Timo A", "Initials": "TA"}, {"Identifier": ["0000-0001-8327-0732"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria."}, {"Identifier": [], "Affiliation": "BioTechMed, Graz, Austria."}], "LastName": "Pferschy-Wenzig", "ForeName": "Eva-Maria", "Initials": "E-M"}, {"Identifier": ["0000-0002-2077-2839"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria."}], "LastName": "Kumpitsch", "ForeName": "Christina", "Initials": "C"}, {"Identifier": ["0000-0002-0927-3270"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria."}], "LastName": "Duller", "ForeName": "Stefanie", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Internal Medicine, Medical University of Graz, Graz, Austria."}], "LastName": "H\u00f6genauer", "ForeName": "Christoph", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Internal Medicine, Medical University of Graz, Graz, Austria."}], "LastName": "Kump", "ForeName": "Patrizia", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany."}], "LastName": "Aziz-Kalbhenn", "ForeName": "Heba", "Initials": "H"}, {"Identifier": ["0000-0002-5183-2232"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany."}, {"Identifier": [], "Affiliation": "Department of Pharmacology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt."}], "LastName": "Ammar", "ForeName": "Ramy M", "Initials": "RM"}, {"Identifier": ["0000-0002-2619-3491"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany."}], "LastName": "Rabini", "ForeName": "Sabine", "Initials": "S"}, {"Identifier": ["0000-0001-6755-6263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "BioTechMed, Graz, Austria."}, {"Identifier": [], "Affiliation": "Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria."}], "LastName": "Moissl-Eichinger", "ForeName": "Christine", "Initials": "C"}, {"Identifier": ["0000-0002-0057-5547"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria."}, {"Identifier": [], "Affiliation": "BioTechMed, Graz, Austria."}], "LastName": "Bauer", "ForeName": "Rudolf", "Initials": "R"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Microbiol Spectr", "NlmUniqueID": "101634614", "ISSNLinking": "2165-0497"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}], "MeshHeadingList": [{"QualifierName": ["microbiology", "metabolism", "drug therapy"], "DescriptorName": "Irritable Bowel Syndrome"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gastrointestinal Microbiome"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["microbiology"], "DescriptorName": "Feces"}, {"QualifierName": [], "DescriptorName": "Biotransformation"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["metabolism", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["metabolism", "classification", "isolation & purification", "drug effects", "genetics"], "DescriptorName": "Bacteria"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["microbiology", "chemistry"], "DescriptorName": "Plants, Medicinal"}], "CoiStatement": "The PhD position of T.A.T. was funded by Bayer Consumer Health (Havelstra\u00dfe 5, 64295 Darmstadt, Germany). H. A.-K., R.M.A., and S.R. are fully employed by Bayer Consumer Health (Havelstra\u00dfe 5, 64295 Darmstadt, Germany). Bayer Consumer Health had no influence on data analysis and interpretation. All other authors report no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Lovell RM, Ford AC. 2012. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10:712\u2013721. doi:10.1016/j.cgh.2012.02.029", "ArticleIdList": ["10.1016/j.cgh.2012.02.029", "22426087"]}, {"Citation": "Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. 2016. Bowel disorders. Gastroenterology 150:1393\u20131407. doi:10.1053/j.gastro.2016.02.031", "ArticleIdList": ["10.1053/j.gastro.2016.02.031", "27144627"]}, {"Citation": "Holtmann GJ, Ford AC, Talley NJ. 2016. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol 1:133\u2013146. doi:10.1016/S2468-1253(16)30023-1", "ArticleIdList": ["10.1016/S2468-1253(16)30023-1", "28404070"]}, {"Citation": "Hadjivasilis A, Tsioutis C, Michalinos A, Ntourakis D, Christodoulou DK, Agouridis AP. 2019. New insights into irritable bowel syndrome: from pathophysiology to treatment. Ann Gastroenterol 32:554\u2013564. doi:10.20524/aog.2019.0428", "ArticleIdList": ["10.20524/aog.2019.0428", "PMC6826071", "31700231"]}, {"Citation": "Ford AC, Lacy BE, Talley NJ. 2017. Irritable bowel syndrome. N Engl J Med 376:2566\u20132578. doi:10.1056/NEJMra1607547", "ArticleIdList": ["10.1056/NEJMra1607547", "28657875"]}, {"Citation": "Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. 2019. The microbiome and irritable bowel syndrome \u2013 a review on the pathophysiology, current research and future therapy. Front Microbiol 10:1136. doi:10.3389/fmicb.2019.01136", "ArticleIdList": ["10.3389/fmicb.2019.01136", "PMC6579922", "31244784"]}, {"Citation": "Sommer F, B\u00e4ckhed F. 2013. The gut microbiota \u2014 masters of host development and physiology. Nat Rev Microbiol 11:227\u2013238. doi:10.1038/nrmicro2974", "ArticleIdList": ["10.1038/nrmicro2974", "23435359"]}, {"Citation": "Kumpitsch C, Fischmeister FPS, Mahnert A, Lackner S, Wilding M, Sturm C, Springer A, Madl T, Holasek S, H\u00f6genauer C, Berg IA, Schoepf V, Moissl-Eichinger C. 2021. Reduced B12 uptake and increased gastrointestinal formate are associated with archaeome-mediated breath methane emission in humans. Microbiome 9:193. doi:10.1186/s40168-021-01130-w", "ArticleIdList": ["10.1186/s40168-021-01130-w", "PMC8464155", "34560884"]}, {"Citation": "Quigley EMM. 2017. Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet? Nat Rev Gastroenterol Hepatol 14:315\u2013320. doi:10.1038/nrgastro.2017.29", "ArticleIdList": ["10.1038/nrgastro.2017.29", "28356581"]}, {"Citation": "Hasan N, Yang H. 2019. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ 7:e7502. doi:10.7717/peerj.7502", "ArticleIdList": ["10.7717/peerj.7502", "PMC6699480", "31440436"]}, {"Citation": "Jeffery IB, Das A, O\u2019Herlihy E, Coughlan S, Cisek K, Moore M, Bradley F, Carty T, Pradhan M, Dwibedi C, Shanahan F, O\u2019Toole PW. 2020. Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption. Gastroenterology 158:1016\u20131028. doi:10.1053/j.gastro.2019.11.301", "ArticleIdList": ["10.1053/j.gastro.2019.11.301", "31843589"]}, {"Citation": "Tap J, Derrien M, T\u00f6rnblom H, Brazeilles R, Cools-Portier S, Dor\u00e9 J, St\u00f6rsrud S, Le Nev\u00e9 B, \u00d6hman L, Simr\u00e9n M. 2017. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 152:111\u2013123. doi:10.1053/j.gastro.2016.09.049", "ArticleIdList": ["10.1053/j.gastro.2016.09.049", "27725146"]}, {"Citation": "Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. 2019. Gut microbiota in patients with irritable bowel syndrome\u2014a systematic review. Gastroenterology 157:97\u2013108. doi:10.1053/j.gastro.2019.03.049", "ArticleIdList": ["10.1053/j.gastro.2019.03.049", "30940523"]}, {"Citation": "Bu F, Tu Y, Wan Z, Tu S. 2023. Herbal medicine and its impact on the gut microbiota in colorectal cancer. Front Cell Infect Microbiol 13:1096008. doi:10.3389/fcimb.2023.1096008", "ArticleIdList": ["10.3389/fcimb.2023.1096008", "PMC10352802", "37469598"]}, {"Citation": "Zhang Q, Bai Y, Wang W, Li J, Zhang L, Tang Y, Yue S. 2023. Role of herbal medicine and gut microbiota in the prevention and treatment of obesity. J Ethnopharmacol 305:116127. doi:10.1016/j.jep.2022.116127", "ArticleIdList": ["10.1016/j.jep.2022.116127", "36603782"]}, {"Citation": "Peterson CT, Sharma V, Uchitel S, Denniston K, Chopra D, Mills PJ, Peterson SN. 2018. Prebiotic potential of herbal medicines used in digestive health and disease. J Altern Complement Med 24:656\u2013665. doi:10.1089/acm.2017.0422", "ArticleIdList": ["10.1089/acm.2017.0422", "PMC6065514", "29565634"]}, {"Citation": "Plamada D, Vodnar DC. 2021. Polyphenols\u2014gut microbiota interrelationship: a transition to a new generation of prebiotics. Nutrients 14:137. doi:10.3390/nu14010137", "ArticleIdList": ["10.3390/nu14010137", "PMC8747136", "35011012"]}, {"Citation": "Luca SV, Macovei I, Bujor A, Miron A, Skalicka-Wo\u017aniak K, Aprotosoaie AC, Trifan A. 2020. Bioactivity of dietary polyphenols: the role of metabolites. Crit Rev Food Sci Nutr 60:626\u2013659. doi:10.1080/10408398.2018.1546669", "ArticleIdList": ["10.1080/10408398.2018.1546669", "30614249"]}, {"Citation": "Mosele JI, Maci\u00e0 A, Motilva MJ. 2015. Metabolic and microbial modulation of the large intestine ecosystem by non-absorbed diet phenolic compounds: a review. Molecules 20:17429\u201317468. doi:10.3390/molecules200917429", "ArticleIdList": ["10.3390/molecules200917429", "PMC6331829", "26393570"]}, {"Citation": "Garc\u00eda-Villalba R, Gim\u00e9nez-Bastida JA, Cort\u00e9s-Mart\u00edn A, \u00c1vila-G\u00e1lvez M\u00c1, Tom\u00e1s-Barber\u00e1n FA, Selma MV, Esp\u00edn JC, Gonz\u00e1lez-Sarr\u00edas A. 2022. Urolithins: a comprehensive update on their metabolism, bioactivity, and associated gut microbiota. Mol Nutr Food Res 66:e2101019. doi:10.1002/mnfr.202101019", "ArticleIdList": ["10.1002/mnfr.202101019", "PMC9787965", "35118817"]}, {"Citation": "H\u00f6gger P. 2013. Nutrition-derived bioactive metabolites produced by gut microbiota and their potential impact on human health. Nutr Med"}, {"Citation": "Sharma A, Lee H-J. 2020. Ginsenoside compound K: insights into recent studies on pharmacokinetics and health-promoting activities. Biomolecules 10:1028. doi:10.3390/biom10071028", "ArticleIdList": ["10.3390/biom10071028", "PMC7407392", "32664389"]}, {"Citation": "Kwon Y-J, Son D-H, Chung T-H, Lee Y-J. 2020. A review of the pharmacological efficacy and safety of licorice root from corroborative clinical trial findings. J Med Food 23:12\u201320. doi:10.1089/jmf.2019.4459", "ArticleIdList": ["10.1089/jmf.2019.4459", "31874059"]}, {"Citation": "Thumann TA, Pferschy-Wenzig E-M, Moissl-Eichinger C, Bauer R. 2019. The role of gut microbiota for the activity of medicinal plants traditionally used in the European Union for gastrointestinal disorders. J Ethnopharmacol 245:112153. doi:10.1016/j.jep.2019.112153", "ArticleIdList": ["10.1016/j.jep.2019.112153", "31408679"]}, {"Citation": "Ottillinger B, Storr M, Malfertheiner P, Allescher H-D. 2013. STW 5 (Iberogast)\u2014a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 163:65\u201372. doi:10.1007/s10354-012-0169-x", "ArticleIdList": ["10.1007/s10354-012-0169-x", "PMC3580135", "23263639"]}, {"Citation": "Madisch A, Holtmann G, Plein K, Hotz J. 2004. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19:271\u2013279. doi:10.1111/j.1365-2036.2004.01859.x", "ArticleIdList": ["10.1111/j.1365-2036.2004.01859.x", "14984373"]}, {"Citation": "Mohamed SS, Abdeltawab NF, Wadie W, Ahmed LA, Ammar RM, Rabini S, Abdel-Aziz H, Khayyal MT. 2021. Effect of the standard herbal preparation, STW5, treatment on dysbiosis induced by dextran sodium sulfate in experimental colitis. BMC Complement Med Ther 21:168. doi:10.1186/s12906-021-03337-8", "ArticleIdList": ["10.1186/s12906-021-03337-8", "PMC8188707", "34103031"]}, {"Citation": "Allescher HD, Burgell R, Malfertheiner P, Mearin F. 2020. Multi-target treatment for irritable bowel syndrome with STW 5: pharmacological modes of action. J Gastrointestin Liver Dis 29:227\u2013233. doi:10.15403/jgld-814", "ArticleIdList": ["10.15403/jgld-814", "32530990"]}, {"Citation": "Schemann M, Landmann M, Kelber O, Ammar RM, Krueger D, Michel K. 2021. Effects of the herbal preparation STW 5\u2010II on in vitro muscle activity in the guinea pig stomach. Neurogastroenterol Motil 33:e13984. doi:10.1111/nmo.13984", "ArticleIdList": ["10.1111/nmo.13984", "32936513"]}, {"Citation": "Thumann TA, Pferschy-Wenzig EM, Aziz-Kalbhenn H, Ammar RM, Rabini S, Moissl-Eichinger C, Bauer R. 2020. Application of an in vitro digestion model to study the metabolic profile changes of an herbal extract combination by UHPLC\u2013HRMS. Phytomedicine 71:153221. doi:10.1016/j.phymed.2020.153221", "ArticleIdList": ["10.1016/j.phymed.2020.153221", "32447246"]}, {"Citation": "Ammar RM, Pferschy-Wenzig EM, Van den Abbeele P, Verstrepen L, Ghyselinck J, Thumann T, Bauer R. 2023. Possible role of the gut microbiome in mediating the beneficial effects of the six-herbal formulation STW 5-II on digestive health. Phytomedicine 119:154996. doi:10.1016/j.phymed.2023.154996", "ArticleIdList": ["10.1016/j.phymed.2023.154996", "37595389"]}, {"Citation": "Isenring J, Bircher L, Geirnaert A, Lacroix C. 2023. In vitro human gut microbiota fermentation models: opportunities, challenges, and pitfalls. Microbiome Res Rep 2:2. doi:10.20517/mrr.2022.15", "ArticleIdList": ["10.20517/mrr.2022.15", "PMC10688811", "38045607"]}, {"Citation": "Brodkorb A, Egger L, Alminger M, Alvito P, Assun\u00e7\u00e3o R, Ballance S, Bohn T, Bourlieu-Lacanal C, Boutrou R, Carri\u00e8re F, et al. . 2019. INFOGEST static in vitro simulation of gastrointestinal food digestion. Nat Protoc 14:991\u20131014. doi:10.1038/s41596-018-0119-1", "ArticleIdList": ["10.1038/s41596-018-0119-1", "30886367"]}, {"Citation": "Rodriguez-Mateos A, Vauzour D, Krueger CG, Shanmuganayagam D, Reed J, Calani L, Mena P, Del Rio D, Crozier A. 2014. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Arch Toxicol 88:1803\u20131853. doi:10.1007/s00204-014-1330-7", "ArticleIdList": ["10.1007/s00204-014-1330-7", "25182418"]}, {"Citation": "Kelber O, Wittwer A, Lapke C, Kroll U, Weiser D, Okpanyi SN, Heilmann J. 2006. Ex vivo/in vitro absorption of STW 5 (Iberogast) and its extract components. Phytomedicine 13:107\u2013113. doi:10.1016/j.phymed.2006.07.002", "ArticleIdList": ["10.1016/j.phymed.2006.07.002", "16920344"]}, {"Citation": "Kastl AJ, Terry NA, Wu GD, Albenberg LG. 2020. The structure and function of the human small intestinal microbiota: current understanding and future directions. Cell Mol Gastroenterol Hepatol 9:33\u201345. doi:10.1016/j.jcmgh.2019.07.006", "ArticleIdList": ["10.1016/j.jcmgh.2019.07.006", "PMC6881639", "31344510"]}, {"Citation": "Braune A, Blaut M. 2016. Bacterial species involved in the conversion of dietary flavonoids in the human gut. Gut Microbes 7:216\u2013234. doi:10.1080/19490976.2016.1158395", "ArticleIdList": ["10.1080/19490976.2016.1158395", "PMC4939924", "26963713"]}, {"Citation": "Han L, Zhao L, Zhou Y, Yang C, Xiong T, Lu L, Deng Y, Luo W, Chen Y, Qiu Q, et al. . 2022. Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity. ISME J 16:983\u2013996. doi:10.1038/s41396-021-01123-5", "ArticleIdList": ["10.1038/s41396-021-01123-5", "PMC8940891", "34750528"]}, {"Citation": "Tom\u00e1s-Barber\u00e1n FA, Selma MV, Esp\u00edn JC. 2016. Interactions of gut microbiota with dietary polyphenols and consequences to human health. Curr Opin Clin Nutr Metab Care 19:471\u2013476. doi:10.1097/MCO.0000000000000314", "ArticleIdList": ["10.1097/MCO.0000000000000314", "27490306"]}, {"Citation": "Navarro del Hierro J, Herrera T, Fornari T, Reglero G, Martin D. 2018. The gastrointestinal behavior of saponins and its significance for their bioavailability and bioactivities. J Funct Foods 40:484\u2013497. doi:10.1016/j.jff.2017.11.032", "ArticleIdList": ["10.1016/j.jff.2017.11.032"]}, {"Citation": "Dingeo G, Brito A, Samouda H, Iddir M, La Frano MR, Bohn T. 2020. Phytochemicals as modifiers of gut microbial communities. Food Funct 11:8444\u20138471. doi:10.1039/D0FO01483D", "ArticleIdList": ["10.1039/D0FO01483D", "32996966"]}, {"Citation": "Theilmann MC, Goh YJ, Nielsen KF, Klaenhammer TR, Barrangou R, Abou Hachem M. 2017. Lactobacillus acidophilus metabolizes dietary plant glucosides and externalizes their bioactive phytochemicals. mBio 8:e01421-17. doi:10.1128/mBio.01421-17", "ArticleIdList": ["10.1128/mBio.01421-17", "PMC5698550", "29162708"]}, {"Citation": "Hugerth LW, Andreasson A, Talley NJ, Forsberg AM, Kjellstr\u00f6m L, Schmidt PT, Agreus L, Engstrand L. 2020. No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut 69:1076\u20131084. doi:10.1136/gutjnl-2019-318717", "ArticleIdList": ["10.1136/gutjnl-2019-318717", "PMC7282555", "31601615"]}, {"Citation": "Mohamed SS, Abdeltawab NF, Wadie W, Ahmed LA, Ammar RM, Rabini S, Abdel-Aziz H, Khayyal MT. 2021. Effect of the standard herbal preparation, STW5, treatment on dysbiosis induced by dextran sodium sulfate in experimental colitis. BMC Complement Med Ther 21:168. doi:10.1186/s12906-021-03337-8", "ArticleIdList": ["10.1186/s12906-021-03337-8", "PMC8188707", "34103031"]}, {"Citation": "Baky MH, Elshahed M, Wessjohann L, Farag MA. 2022. Interactions between dietary flavonoids and the gut microbiome: a comprehensive review. Br J Nutr 128:577\u2013591. doi:10.1017/S0007114521003627", "ArticleIdList": ["10.1017/S0007114521003627", "34511152"]}, {"Citation": "Mosele JI, Mart\u00edn-Pel\u00e1ez S, Maci\u00e0 A, Farr\u00e0s M, Valls R-M, Catal\u00e1n \u00da, Motilva M-J. 2014. Study of the catabolism of thyme phenols combining in vitro fermentation and human intervention. J Agric Food Chem 62:10954\u201310961. doi:10.1021/jf503748y", "ArticleIdList": ["10.1021/jf503748y", "25339317"]}, {"Citation": "Tomas\u2010Barberan F, Garc\u00eda\u2010Villalba R, Quartieri A, Raimondi S, Amaretti A, Leonardi A, Rossi M. 2014. In vitro transformation of chlorogenic acid by human gut microbiota. Mol Nutr Food Res 58:1122\u20131131. doi:10.1002/mnfr.201300441", "ArticleIdList": ["10.1002/mnfr.201300441", "24550206"]}, {"Citation": "Akao T. 2001. Effect of pH on metabolism of glycyrrhizin, glycyrrhetic acid and glycyrrhetic acid monoglucuronide by collected human intestinal flora. Biol Pharm Bull 24:1108\u20131112. doi:10.1248/bpb.24.1108", "ArticleIdList": ["10.1248/bpb.24.1108", "11642312"]}, {"Citation": "Akao T, Akao T, Kobashi K. 1987. Glycyrrhizin beta-D-glucuronidase of Eubacterium sp. from human intestinal flora. Chem Pharm Bull 35:705\u2013710. doi:10.1248/cpb.35.705", "ArticleIdList": ["10.1248/cpb.35.705", "3594680"]}, {"Citation": "Akao T. 2000. Hasty effect on the metabolism of glycyrrhizin by Eubacterium sp. GLH with Ruminococcus sp. PO1-3 and Clostridium innocuum ES24-06 of human intestinal bacteria. Biol Pharm Bull 23:6\u201311. doi:10.1248/bpb.23.6", "ArticleIdList": ["10.1248/bpb.23.6", "10706402"]}, {"Citation": "Park HY, Kim NY, Han MJ, Bae EA, Kim DH. 2005. Purification and characterization of two novel \u03b2-D-glucuronidases converting glycyrrhizin to 18\u03b2-glycyrrhetinic acid-3-O-\u03b2-D-glucuronide from Streptococcus LJ-22. J Microbiol Biotechnol 15:792\u2013799."}, {"Citation": "Sakuma K, Kitahara M, Kibe R, Sakamoto M, Benno Y. 2006. Clostridium glycyrrhizinilyticum sp. nov., a glycyrrhizin-hydrolysing bacterium isolated from human faeces. Microbiol Immunol 50:481\u2013485. doi:10.1111/j.1348-0421.2006.tb03818.x", "ArticleIdList": ["10.1111/j.1348-0421.2006.tb03818.x", "16858139"]}, {"Citation": "Wei B, Wang PP, Yan ZX, Yan R. 2018. Characteristics and molecular determinants of a highly selective and efficient glycyrrhizin-hydrolyzing \u03b2-glucuronidase from Staphylococcus pasteuri 3I10. Appl Microbiol Biotechnol 102:9193\u20139205. doi:10.1007/s00253-018-9285-x", "ArticleIdList": ["10.1007/s00253-018-9285-x", "30109395"]}, {"Citation": "Braune A, G\u00fctschow M, Blaut M. 2019. An NADH-dependent reductase from Eubacterium ramulus catalyzes the stereospecific heteroring cleavage of flavanones and flavanonols. Appl Environ Microbiol 85:e01233-19. doi:10.1128/AEM.01233-19", "ArticleIdList": ["10.1128/AEM.01233-19", "PMC6752008", "31375488"]}, {"Citation": "Petru\u013eov\u00e1-Porack\u00e1 V, Rep\u010d\u00e1k M, Vilkov\u00e1 M, Imrich J. 2013. Coumarins of Matricaria chamomilla L.: aglycones and glycosides. Food Chem 141:54\u201359. doi:10.1016/j.foodchem.2013.03.004", "ArticleIdList": ["10.1016/j.foodchem.2013.03.004", "23768326"]}, {"Citation": "Indahl SR, Scheline RR. 1971. The metabolism of umbelliferone and herniarin in rats and by the rat intestinal microflora. Xenobiotica 1:13\u201324. doi:10.3109/00498257109044375", "ArticleIdList": ["10.3109/00498257109044375", "5163172"]}, {"Citation": "Bel-Rhlid R, Crespy V, Pag\u00e9-Zoerkler N, Nagy K, Raab T, Hansen CE. 2009. Hydrolysis of rosmarinic acid from rosemary extract with esterases and Lactobacillus johnsonii in vitro and in a gastrointestinal model. J Agric Food Chem 57:7700\u20137705. doi:10.1021/jf9014262", "ArticleIdList": ["10.1021/jf9014262", "19658402"]}, {"Citation": "Couteau D, McCartney AL, Gibson GR, Williamson G, Faulds CB. 2001. Isolation and characterization of human colonic bacteria able to hydrolyse chlorogenic acid. J Appl Microbiol 90:873\u2013881. doi:10.1046/j.1365-2672.2001.01316.x", "ArticleIdList": ["10.1046/j.1365-2672.2001.01316.x", "11412317"]}, {"Citation": "Fritsch C, J\u00e4nsch A, Ehrmann MA, Toelstede S, Vogel RF. 2017. Characterization of cinnamoyl esterases from different lactobacilli and bifidobacteria. Curr Microbiol 74:247\u2013256. doi:10.1007/s00284-016-1182-x", "ArticleIdList": ["10.1007/s00284-016-1182-x", "27999938"]}, {"Citation": "Peppercorn MA, Goldman P. 1971. Caffeic acid metabolism by bacteria of the human gastrointestinal tract. J Bacteriol 108:996\u20131000. doi:10.1128/jb.108.3.996-1000.1971", "ArticleIdList": ["10.1128/jb.108.3.996-1000.1971", "PMC247180", "5003182"]}, {"Citation": "Desire O, Rivi\u00e8re C, Razafindrazaka R, Goossens L, Moreau S, Guillon J, Uverg-Ratsimamanga S, Andriamadio P, Moore N, Randriantsoa A, Raharisololalao A. 2010. Antispasmodic and antioxidant activities of fractions and bioactive constituent davidigenin isolated from Mascarenhasia arborescens. J Ethnopharmacol 130:320\u2013328. doi:10.1016/j.jep.2010.05.017", "ArticleIdList": ["10.1016/j.jep.2010.05.017", "20580662"]}, {"Citation": "Sato Y, He JX, Nagai H, Tani T, Akao T. 2007. Isoliquiritigenin, one of the antispasmodic principles of Glycyrrhiza ularensis roots, acts in the lower part of intestine. Biol Pharm Bull 30:145\u2013149. doi:10.1248/bpb.30.145", "ArticleIdList": ["10.1248/bpb.30.145", "17202675"]}, {"Citation": "Bakr AF, Shao P, Farag MA. 2022. Recent advances in glycyrrhizin metabolism, health benefits, clinical effects and drug delivery systems for efficacy improvement; a comprehensive review. Phytomedicine 99:153999. doi:10.1016/j.phymed.2022.153999", "ArticleIdList": ["10.1016/j.phymed.2022.153999", "35220130"]}, {"Citation": "Leite CDS, Bonaf\u00e9 GA, Carvalho Santos J, Martinez CAR, Ortega MM, Ribeiro ML. 2022. The anti-inflammatory properties of licorice (Glycyrrhiza glabra)-derived compounds in intestinal disorders. Int J Mol Sci 23:4121. doi:10.3390/ijms23084121", "ArticleIdList": ["10.3390/ijms23084121", "PMC9025446", "35456938"]}, {"Citation": "Liu Z, Zhang Z, Chen X, Ma P, Peng Y, Li X. 2023. Citrate and hydroxycinnamate derivatives from Mume Fructus protect LPS-injured intestinal epithelial cells by regulating the FAK/PI3K/AKT signaling pathway. J Ethnopharmacol 301:115834. doi:10.1016/j.jep.2022.115834", "ArticleIdList": ["10.1016/j.jep.2022.115834", "36270558"]}, {"Citation": "Kroll U, Cordes C. 2006. Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 13:12\u201319. doi:10.1016/j.phymed.2006.03.016", "ArticleIdList": ["10.1016/j.phymed.2006.03.016", "16857355"]}, {"Citation": "Minekus M, Alminger M, Alvito P, Ballance S, Bohn T, Bourlieu C, Carri\u00e8re F, Boutrou R, Corredig M, Dupont D, et al. . 2014. A standardised static in vitro digestion method suitable for food \u2013 an international consensus. Food Funct 5:1113\u20131124. doi:10.1039/c3fo60702j", "ArticleIdList": ["10.1039/c3fo60702j", "24803111"]}, {"Citation": "Drossman DA. 2016. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology 150:1262\u20131279. doi:10.1053/j.gastro.2016.02.032", "ArticleIdList": ["10.1053/j.gastro.2016.02.032", "27144617"]}, {"Citation": "Francis CY, Morris J, Whorwell PJ. 1997. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11:395\u2013402. doi:10.1046/j.1365-2036.1997.142318000.x", "ArticleIdList": ["10.1046/j.1365-2036.1997.142318000.x", "9146781"]}, {"Citation": "Pferschy-Wenzig EM, Koskinen K, Moissl-Eichinger C, Bauer R. 2017. A combined LC-MS metabolomics- and 16S rRNA sequencing platform to assess interactions between herbal medicinal products and human gut bacteria in vitro: a pilot study on willow bark extract. Front Pharmacol 8:893. doi:10.3389/fphar.2017.00893", "ArticleIdList": ["10.3389/fphar.2017.00893", "PMC5733343", "29326584"]}, {"Citation": "Nadkarni MA, Martin FE, Jacques NA, Hunter N. 2002. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology (Reading) 148:257\u2013266. doi:10.1099/00221287-148-1-257", "ArticleIdList": ["10.1099/00221287-148-1-257", "11782518"]}, {"Citation": "Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G, Knight R. 2012. Ultra-high-throughput microbial community analysis on the Illumina Hiseq and Miseq platforms. ISME J 6:1621\u20131624. doi:10.1038/ismej.2012.8", "ArticleIdList": ["10.1038/ismej.2012.8", "PMC3400413", "22402401"]}, {"Citation": "Klymiuk I, Bambach I, Patra V, Trajanoski S, Wolf P. 2016. 16S based microbiome analysis from healthy subjects\u2019 skin swabs stored for different storage periods reveal phylum to genus level changes. Front Microbiol 7:2012. doi:10.3389/fmicb.2016.02012", "ArticleIdList": ["10.3389/fmicb.2016.02012", "PMC5167739", "28066342"]}, {"Citation": "Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, et al. . 2019. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 37:852\u2013857. doi:10.1038/s41587-019-0209-9", "ArticleIdList": ["10.1038/s41587-019-0209-9", "PMC7015180", "31341288"]}, {"Citation": "Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods 13:581\u2013583. doi:10.1038/nmeth.3869", "ArticleIdList": ["10.1038/nmeth.3869", "PMC4927377", "27214047"]}, {"Citation": "Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Gl\u00f6ckner FO. 2013. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 41:D590\u2013D596. doi:10.1093/nar/gks1219", "ArticleIdList": ["10.1093/nar/gks1219", "PMC3531112", "23193283"]}, {"Citation": "Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. 2018. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome 6:226. doi:10.1186/s40168-018-0605-2", "ArticleIdList": ["10.1186/s40168-018-0605-2", "PMC6298009", "30558668"]}, {"Citation": "Dietrich A, Matchado MS, Zwiebel M, \u00d6lke B, Lauber M, Lagkouvardos I, Baumbach J, Haller D, Brandl B, Skurk T, Hauner H, Reitmeier S, List M. 2022. Namco: a microbiome explorer. Microb Genom 8:mgen000852. doi:10.1099/mgen.0.000852", "ArticleIdList": ["10.1099/mgen.0.000852", "PMC9484756", "35917163"]}, {"Citation": "Mauri M, Elli T, Caviglia G, Uboldi G, Azzi M. 2017. RAWGraphs, p 1\u20135. In Proceedings of the 12th biannual conference on Italian SIGCHI chapter. ACM, New York, NY, USA."}, {"Citation": "Gloor GB, Macklaim JM, Fernandes AD. 2016. Displaying variation in large datasets: plotting a visual summary of effect sizes. J Comput Graph Stat 25:971\u2013979. doi:10.1080/10618600.2015.1131161", "ArticleIdList": ["10.1080/10618600.2015.1131161"]}]}], "History": [{"Year": "2024", "Month": "6", "Day": "5", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "5", "Day": "13", "Hour": "12", "Minute": "53"}, {"Year": "2024", "Month": "5", "Day": "13", "Hour": "9", "Minute": "13"}, {"Year": "2024", "Month": "5", "Day": "13"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38738925", "PMC11237759", "10.1128/spectrum.04031-23"]}}]}